Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FY1W
|
|||
| Former ID |
DIB001969
|
|||
| Drug Name |
Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy
|
|||
| Synonyms |
Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
University of Alabama at Birmingham
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thymidine kinase 1 (TK1) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00964756) A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.